EP0530224A1 - Nouveaux glycosides steroides utiles pour la detection precoce de l'hypertension - Google Patents

Nouveaux glycosides steroides utiles pour la detection precoce de l'hypertension

Info

Publication number
EP0530224A1
EP0530224A1 EP91908957A EP91908957A EP0530224A1 EP 0530224 A1 EP0530224 A1 EP 0530224A1 EP 91908957 A EP91908957 A EP 91908957A EP 91908957 A EP91908957 A EP 91908957A EP 0530224 A1 EP0530224 A1 EP 0530224A1
Authority
EP
European Patent Office
Prior art keywords
compound
alkyl
amount
atpase
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91908957A
Other languages
German (de)
English (en)
Inventor
Margaret A. Kenny
Suhail Ahmad
Sohail Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of EP0530224A1 publication Critical patent/EP0530224A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C07J19/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides

Definitions

  • the present invention relates generally to the purification, characterization, derivatization and uses of a series of compounds.
  • This invention is more particularly related to the detection of a compound, e.g., to screen for or monitor hypertensive individuals or to correct for interference in the measurement of digoxin levels in patients, and to the use of a compound or a derivative thereof as a pressor agent, potassium sparing diuretic, natriuretic or agent that alters cellular calcium levels.
  • a compound has the formula:
  • derivatives having the formula:
  • R1-R5 are independently selected from H or X, where X is selected from the group consisting of OH, F, Cl, Br, I, NH2, CN, OZ and OCOZ, where Z is an alkyl group from 1 to 6 carbon atoms;
  • Rg is H, X, CH3, CHO or CE X;
  • R7 is H or X;
  • Rg is X or 0-(Sugar) n ;
  • R9 is CH3;
  • R10-R12 are independently selected from H or X;
  • R13-R15 are independently selected from H, F, Cl, Br, I, alkyl or haloalkyl group from 1 to 6 carbon atoms;
  • R is a keto, OH, alkyl or haloalkyl group from 1 to 6 carbon atoms and C23 is sp 2 or sp ,
  • ring B is saturated or unsaturated at C5-C6;
  • ring C is saturated or unsaturated at C
  • derivatives have the formula depicted immediately above, wherein R1-R5 are independently selected from H or X, where X is selected from the group consisting of OH, F, Cl, Br, I, NH2, CN, OZ and OCOZ, where Z is an alkyl group from 1 to 6 carbon atoms; Rg is H, X, CH3, CHO or CH2X; R7 is H or X; Rg is H; R9 is CH3; R10-R12 ⁇ independently selected from H or X; R13-R15 are independently selected from H, F, Cl, Br, I, alkyl or haloalkyl group from 1 to 6 carbon atoms; R ⁇ 6 is a keto, OH, alkyl or haloalkyl group from 1 to 6 carbon atoms and C23 is sp 2 or sp 3 ; ring B is saturated or unsaturated at C5-C5; ring C is saturated or unsaturated at Cg-C ⁇ 4; ring D is
  • R1-R5 are independently selected from H or X, where X is selected from the group consisting of OH, F, Cl, Br, I, NH2, CN, OZ and OCOZ, where Z is an alkyl group from 1 to 6 carbon atoms;
  • Rg is H, X, CH3, CHO or CH2X;
  • R7 is H or X;
  • Rg is X;
  • R9 is CH3;
  • R10-R12 are independently selected from H or X;
  • R13- R ⁇ 4 are independently selected from H, F, Cl, Br, I, alkyl or haloalkyl group from 1 to 6 carbon atoms;
  • R ⁇ 5 is a keto, OH, alkyl or haloalkyl group from 1 to 6 carbon atoms and C23 is sp 2 or sp 3 ;
  • ring B is saturated or unsaturated at C5-C ;
  • ring C is saturated or unsaturated at Cg-C * i4
  • derivatives have the formula depicted immediately above, wherein R1-R5 are independently selected from H or X, where X is selected from the group consisting of OH, F, Q, Br, I, NH2, CN, OZ and OCOZ, where Z is an alkyl group from 1 to 6 carbon atoms; Rg is H, X, CH3, CHO or CH2X; R7 is H or X; Rg is H; R9 is CH3; R10-R12 are independently selected from H or X; R13-R14 are independently selected from H, F, Cl, Br, I, alkyl or haloalkyl group from 1 to 6 carbon atoms; R 15 is a keto, OH, alkyl or haloalkyl group from 1 to 6 carbon atoms and C23 is sp 2 or sp 3 ; ring B is saturated or unsaturated at C5-C ; ring C is saturated or unsaturated at Cg-Cj4; ring D is saturated or
  • derivatives also have the formula depicted immediately above, wherein R1-R5 are independently selected from H or X, where X is selected from the group consisting of OH, F, Cl, Br, I, NH2, CN, OZ and OCOZ, where Z is an alkyl group from 1 to 6 carbon atoms; Rg is H, X, CH3,
  • R7 is H or X
  • Rg is 0-(Sugar) n
  • R9 is CH3
  • R10-R12 are independently selected from H or X
  • R13-R14 are independently selected from H, F, Cl, Br, I, alkyl or haloalkyl group from 1 to 6 carbon atoms
  • R15 is a keto, OH, alkyl or haloalkyl group from 1 to 6 carbon atoms and C23 is sp 2 or sp 3
  • ring B is saturated or unsaturated at C5-Cg
  • ring C is saturated or unsaturated at Cg-C ⁇ 4
  • ring D is saturated or unsaturated at C14-C15 or Ci5-C ⁇ g
  • sugar is independently selected from hexoses wherein at least one of the sugars attached to C3 is a glucose, a mannose, a fructose or a galactose
  • n is an integer from 2 to 5.
  • the present invention is also directed toward methods for detecting the presence or amount of a compound having the following structure:
  • the methods comprise the step of: testing a biological fluid sample for the presence or amount of a compound described immediately above.
  • the step of testing comprises the steps of: (a) contacting a biological fluid sample with an antibody specific for a compound described immediately above under conditions and for a time sufficient to allow immunocomplexes to form therebetween; and (b) detecting the presence or amount of one or more immunocomplexes formed between the antibody and the compound, thereby dete ⁇ nining the presence or amount of the compound.
  • the step of testing comprises the steps of: (a) contacting a biological fluid sample with at least two antibodies, the combination of which are specific for a compound described immediately above under conditions and for a time sufficient to allow immunocomplexes to form therebetween; and (b) detecting the presence or amount of one or more immunocomplexes formed between each of the antibodies and the compound, thereby determining the presence or amount of the compound.
  • the step of testing comprises the steps of:
  • the step of testing comprises the steps of: (a) contacting an aliquot of a biological fluid sample with a Ca 2+ -ATPase preparation; (b) detecting the presence or amount of specific binding of a substance in the biological fluid sample to the Ca 2+ -ATPase; (c) contacting another aliquot of the biological fluid sample with a Na + , K + -ATPase preparation; (d) detecting the presence or amount of specific binding of a substance in the biological fluid sample to the Na + , K + -ATPase; and (e) determining the presence or amount of a compound described immediately above by the presence or amount of specific binding to both the Ca 2+ -ATPase and the Na + , K + -ATPase.
  • the step of testing comprises the steps of: (a) contacting an aliquot of a biological fluid sample with a Ca 2+ -ATPase preparation and substrates permitting enzymatic activity by the Ca 2+ -ATPase;
  • Another method provided by the present invention for detecting the presence or amount of a compound described immediately above comprises the steps of: (a) contacting a biological fluid sample with a binding partner specific for the compound under conditions and for a time sufficient to allow complexes to form therebetween; and (b) detecting the presence or amount of one or more complexes formed between the binding partner and the compound, thereby determining the presence or amount of the compound. Additional methods provided for detecting the presence or amount of a compound described immediately above involve specific inhibition of Ca + -ATPase enzymatic activity or specific binding to the Ca 2+ -ATPase.
  • the method comprises the steps of: (a) contacting a biological fluid sample with a Ca 2+ - ATPase preparation and substrates permitting enzymatic activity by the Ca + - ATPase; and (b) detecting the presence or amount of specific inhibition of the
  • the method comprises the steps of:
  • the present invention also provides methods for detecting the predisposition of a warm-blooded animal to hypertension.
  • the methods comprise detecting the presence or amount of a compound described immediately above in a biological fluid sample of a warm-blooded animal, and therefrom determining the predisposition of the warm-blooded animal to hypertension.
  • the present invention is also directed toward methods for correcting for interference in the measurement of digoxin levels in patients.
  • the method comprises detecting the amount of a compound described immediately above in a biological fluid sample of a warm-blooded animal administered digoxin.
  • a compound disclosed above may be used as an active therapeutic substance or in a composition by combination with a pharmaceutically acceptable carrier or diluent.
  • compositions may be used in the manufacture of a medicament for elevating blood pressure, for increasing diuresis, for increasing natriuresis, or for altering cellular calcium levels.
  • Figure 1 depicts a synthetic scheme to produce a compound of the present invention and certain derivatives thereof.
  • Figure 2 depicts an alternative synthetic scheme to produce a compound of the present invention and certain derivatives thereof.
  • Figure 3 graphically illustrates a dose-response relationship for the inhibition of calmodulin-free Ca 2+ -ATPase by a compound of the present invention.
  • the percentage of inhibition of calmodulin-free Ca 2+ -ATPase activity is shown as a function of the compound concentration.
  • the specific activity of the Ca 2+ -ATPase in the absence of the compound was 10.5 nmole/min/mg protein.
  • the IC50 of the compound was calculated as 20 ng/ml.
  • Figure 4 graphically illustrates a dose-response relationship for the inhibition of calmodulin-activated Ca 2+ -ATPase by a compound of the present invention.
  • the percentage of inhibition of calmodulin-activated Ca 2+ -ATPase activity is shown as a function of the compound concentration.
  • the specific activity of the calmodulin-activated Ca 2+ -ATPase in the absence of the compound was 59.3 nmole/min/mg protein.
  • the IC50 of the compound was approximately 20 ng/ml.
  • Figure 5 graphically illustrates a dose-response relationship for the inhibition of Na + , K + -ATPase by a compound of the present invention.
  • the percentage of inhibition of Na + ,K + -ATPase activity is shown as a function of the compound concentration.
  • the specific activity of the Na + , K + -ATPase in the absence of the compound was 5.8 nmole/min/mg protein.
  • the IC50 of the compound was approximately 20 ng/ml.
  • Figure 6 shows a dose-response curve for inhibition of an isolated Ca 2+ -ATPase preparation as a function of the concentration of a compound of the present invention.
  • the enzyme was isolated by calmodulin affinity chromatography and stabilized with BHT.
  • Ca 2+ -ATPase activity was measured by release of inorganic phosphate.
  • the IC50 for inhibition of Ca 2+ -ATPase activity by the compound was calculated to be 51 nM.
  • Sugar - as used herein, includes naturally occurring monosaccharides and derivatives, such as replacement of one or more hydroxyl groups with acetate groups.
  • the sugar may exist in a pyranose or furanose form and may be linked by ⁇ or ⁇ , 1-4 or 1-6 ether linkages.
  • Antibody - as used herein includes both polyclonal and monoclonal antibodies and may be an intact molecule, a fragment thereof, or a functional equivalent thereof.
  • the antibody may be genetically engineered.
  • Examples of antibody fragments include F(ab')2 Fab', Fab and Fv.
  • a compound has been isolated from humans and purified. Suitable sources of starting material for such purification include a wide variety of biological fluids, e.g., blood, plasma, serum, plasma ultrafiltrate, urine, saliva, sweat and tears. Briefly, a biological fluid sample is subjected to ultrafiltration to isolate the low molecular weight compounds.
  • the ultrafiltrate is extracted with benzene.
  • the aqueous phase is extracted with ethe ⁇ acetone (5:7), the extraction repeated two or more times, and the organic layers pooled.
  • the solvent is removed, the residue reconstituted in an aqueous chloroform methanol solution, and fractionated by silicic acid column chromatography. Selected fractions are pooled, solvent removed, HPLC solvent added, applied to a C18 reverse phase column and eluted by gradient.
  • the C18-HPLC step is repeated to yield a compound of the present invention. Given the teachings provided herein, it would be evident to those skilled in the art that modifications of this procedure would be suitable.
  • a purified compound was determined by structural analysis to be a glycoside having a molecular weight of 716, a molecular formula of C35H5g0 ⁇ 5, and the following formula:
  • Structural elucidation permits the preparation of synthetic compounds by standard techniques. It will be evident to those skilled in the art that a variety of derivatives may also be prepared.
  • the sugar portion of a compound described immediately above may be replaced or joined with one or more pentoses or other hexoses or combinations of pentoses and hexoses.
  • the sugar residues need not be identical, i.e., each sugar residue may be independently selected from pentoses and hexoses.
  • Suitable hexoses include glucose, mannose, fructose and galactose.
  • the number of sugar residues will be from 1 to 5. Particularly preferred are two galactoses, two glucoses, or one glucose and one galactose.
  • the aglycone portion provides sites for substitution.
  • derivatives are provided having the formula:
  • substituents may be incorporated at the sites for substitution, designated as Ri-Rjg.
  • Suitable substituents include H, CH3, CHO, keto, alkyl or haloalkyl from 1 to 6 carbon atoms, 0-(sugar) n where n is typically from 1 to 5, and X and CH 2 X where X is typically OH, F, Cl, Br, I, NH 2 , CN, OZ and OCOZ where Z is typically an alkyl group from 1 to 6 carbon atoms.
  • C23 may be sp 3 or sp 2 (i.e., a single or double bond between Rjg and C23).
  • the four rings may be saturated or unsaturated.
  • typical locations of double bonds are C5-Cg, Cg-C ⁇ 4, C14-C15, and C ⁇ 5-C ⁇ .
  • R ⁇ -R ⁇ g is attached to a ring carbon not participating in a double bond, there will be two substituents attached to the ring carbon.
  • OH and H may be attached to C12, and CH3 and H attached to C13.
  • derivatives are provided in which the lactone ring is unsaturated at C ⁇ Q- 22- Such derivatives have the formula:
  • R1-R15 A variety of substituents may be incorporated at the sites for substitution, designated as R1-R15. Suitable substituents include H, CH3, CHO, keto, alkyl or haloalkyl from 1 to 6 carbon atoms, 0-(sugar) n where n is typically from 1 to 5, and X and CH2X where X is typically OH, F, Cl, Br, I, NH2, CN, OZ and OCOZ where Z is typically an alkyl group from 1 to 6 carbon atoms.
  • C23 may be sp 3 or sp 2 (i.e., a single or double bond between R15 and C23).
  • the four rings may be saturated or unsaturated.
  • typical locations of double bonds are C5-Cg, Cg-C ⁇ 4, C14-C15, and C ⁇ 5-C ⁇ .
  • R ⁇ -R ⁇ 5 is attached to a ring carbon not participating in a double bond, there will be two substituents attached to the ring carbon.
  • OH and H may be attached to C ⁇ 2 > and CH3 and H attached to C13.
  • compounds of the present invention may be used for numerous diagnostic and therapeutic purposes.
  • Representative diagnostic uses include screening, or monitoring, for essential hypertension and correcting for interference by the compound in the measurement of digoxin levels.
  • essential hypertension is a widespread problem and there exists a need for improved methods for the identification of hypertensive individuals.
  • the present invention discloses that a compound is associated with essential hypertension and thus individuals may be screened for hypertension by testing for the presence or amount of this compound.
  • hypertensive or pre-hypertensive individuals, receiving or not receiving dietary or pharmacological therapies may be monitored by testing for this compound.
  • Digoxin is widely used in the treatment of cardiac irregularities.
  • the narrow therapeutic index for digoxin necessitates an accurate and reliable method for the measurement of serum digoxin concentration.
  • the disclosure of the present invention shows that a purified compound of the present invention binds anti-digoxin antibodies and therefore interferes with the measurement of digoxin concentrations in the serum.
  • a compound of the present invention may be used to screen for anti-digoxin antibodies possessing minimal or no cross- reactivity with the compound.
  • a compound may be attached to a solid support and anti-digoxin sera contacted with the derivatized support to remove antibodies showing cross-reactivity.
  • detection of the amount of a compound in a biological fluid, such as serum permits the correction for its interference with the measurement of digoxin concentrations.
  • Compounds of the present invention may be detected in a variety of ways, including chemical, immunological and receptor-based assays. Such assays may involve the use of binding partners such as antibodies or receptors. Detection of the compound may be qualitative or quantitative, and a biological fluid sample may be tested in vitro or in vivo. Suitable biological fluid samples from a warm ⁇ blooded animal, such as a human, include those described above. In one embodiment, a biological fluid sample is tested for the presence of a compound through the use of an antibody specific for the compound (i.e., with a binding affinity of about 10' liters/mol or higher) or the use of two or more antibodies, the combination of which are specific for the compound.
  • the antibodies may be polyclonal or monoclonal antibodies.
  • polyclonal antibodies may be produced by immunization of an animal and subsequent collection of its sera. Immunization is accomplished, for example, by a systemic administration, such as by subcutaneous, intrasplenic or intramuscular injection, into a rabbit, rat or mouse. It is generally preferred to follow the initial immunization with one or more booster immunizations prior to sera collection. Such methodology is well known and described in a number of references.
  • MAbs monoclonal antibodies
  • MAbs may be generally produced by the method of Kohler and Milstein (Nature 256:495-497, 1975; Eur. J. Immunol. 6:511-519, 1976). Briefly, cells of lymph nodes and/or spleens of an animal immunized with a compound described above are fused with myeloma cells to form hybrid cell lines ("hybridomas" or "clones"). Each hybridoma secretes a single type of immunoglobulin specific for the compound, and, like the myeloma cells, has the potential for indefinite cell division.
  • Suitable MAbs include those of murine or human origin, or chimeric antibodies such as those which combine portions of both human and murine antibodies (i.e., antigen binding region of murine antibody plus constant regions of human antibody).
  • Human and chimeric antibodies may be produced using methods well known by those skilled in the art. Human antibodies and chimeric human-mouse antibodies are advantageous for in vivo uses because they are less likely than murine antibodies to cause the production of anti-antibodies when administered clinically.
  • An alternative to the production of MAbs via hybridomas is the creation of MAb expression libraries using bacteriophage and bacteria (e.g., Sastry et al., Proc. Natl. Acad. Sci. USA £6:5728-5732, 1989; Huse et al., Science 246:1275-1281, 1989).
  • Compounds of the present invention are preferably conjugated before administration as an antigen in order to enhance elicitation of an antibody response in the host animal and/or direct antibody production to particular epitopes.
  • the lactone ring on the compound may be first opened, e.g., by reductive ozonolysis.
  • This modified compound with an open lactone ring is coupled to a methylated or alkylated carrier molecule, such as methylated bovine serum albumin (BSA).
  • BSA methylated bovine serum albumin
  • Patent No.4,767,720 to Lingwood (this patent and those disclosed below are herein incorporated by reference).
  • a conjugate is formed in which a carrier is covalently bound to a compound through the opened lactone ring.
  • Such a conjugate leaves the sugar portion of a compound the most exposed to elicit an antibody response.
  • the antibodies generated will have rninimal cross reactivity with digoxin because the sugar groups of the compounds described above are different from the sugar groups of digoxin.
  • a carrier can be bound to a compound by a sugar group to leave the aglycone portion, and particularly the ketone ring end, exposed as an epitope to elicit an antibody response.
  • the conjugation may be accomplished by oxidizing a sugar group (e.g., U.S. Patent No. 4,671,958 to Rodwell et al.) of a compound to generate an active functional group.
  • the activated sugar moiety is then coupled to a carrier, such as methylated BSA.
  • suitable carriers include thyroglobulin.
  • Detection of the presence or amount of immunocomplexes formed between a compound described above and antibodies specific for the compound may be accomplished by a variety of known techniques, such as radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISA).
  • the detection may be qualitative or quantitative, i.e., the number of immunocomplexes is measured.
  • the level of compound in a sample may be determined from the number of immunocomplexes measured by comparison to values obtained for known concentrations of the compound.
  • Suitable immunoassays include the double monoclonal antibody sandwich immunoassay technique of David et al. (U.S. Patent 4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide et al, in Kirkham and Hunter, eds., Radioimmunoassav Methods. E. and S. Livingstone, Edinburgh, 1970); the "western blot" method of Gordon et al. (U.S. Patent 4,452,901); immunoprecipitation of labeled ligand (Brown et al., J. Biol. Chem. 255:4980- 4983, 1980); enzyme-linked immunosorbent assays as described by, for example, Raines and Ross (J.
  • the antibodies may either be labeled or unlabeled.
  • unlabeled antibodies find use in agglutination assays.
  • unlabeled antibodies can be used in combination with labeled molecules that are reactive with immunocomplexes, or in combination with labeled antibodies (second antibodies) that are reactive with the antibody directed against the compound, such as antibodies specific for immunoglobulin.
  • the antibodies can be directly labeled.
  • the reporter group can include radioisotopes, fluorophores, enzymes, luminescers, or dye particles.
  • a reporter group is bound to the antibody.
  • the step of detecting immunocomplexes involves removing substantially any unbound antibody and then detecting the presence or amount of the reporter group. Unbound antibody is antibody which has not bound to the compound.
  • a reporter group is bound to a second antibody capable of binding to the antibodies specific for the compound.
  • the step of detecting immunocomplexes involves (a) removing substantially any unbound antibody (i.e., antibody not bound to the compound), (b) adding the second antibody, (c) removing substantially any unbound second antibody and then (d) detecting the presence or amount of the reporter group.
  • the antibody specific for the compound is derived from a mouse
  • the second antibody is an anti-murine antibody.
  • a reporter group is bound to a molecule capable of binding to the immunocomplexes.
  • the step of detecting involves (a) adding the molecule, (b) removing substantially any unbound molecule, and then (c) detecting the presence or amount of the reporter group.
  • An example of a molecule capable of binding to the immunocomplexes is protein A.
  • labeled antibodies labeled second antibodies or labeled molecules reactive with immunocomplexes generally, is an immunoassay employing a labeled compound.
  • a compound present in a sample will compete with labeled compound for the antibodies.
  • compound labels include fluorescent labels, radioisotopes, and chemimajnescent labels.
  • Chemiluminescent labels include lucigenin, acridinium derivatives (e.g., 10,10'-dimethyl-9,9'-biacridinium dinitrate), luminol, isoluminol and pyrogallol.
  • a chemiluminescent form of a compound may be used in a luminescent immunoassay, a luminescent enzyme immunoassay, a luminescent cofactor immunoassay and a luminescent enzyme-multiplied immunoassay technique.
  • a luminescent label essentially replaces the radioisotopic label of the typical RIA-type assay.
  • a compound having been labeled with luminol for example, competes with the compound in a sample for a limited amount of antibody specific for the compound.
  • antibody-bound luminol can be detected by the addition of hydrogen peroxide and a catalyst.
  • Other oxidation systems can be used, including hydrogen peroxide- microperoxidase, hydrogen peroxide-hematin, hydrogen peroxide-lactoperoxidase, and persulfate.
  • a compound may be labeled with an enzyme that can either catalyze a luminescent reaction (e.g., peroxidase or luciferase) or produce a substrate for a luminescent reaction.
  • a luminescent reaction e.g., peroxidase or luciferase
  • the second approach can increase assay sensitivity and has been called an amplified bioluminescent immunoassay.
  • a luminescent cofactor immunoassay uses a compound in the form of a conjugate with a cofactor.
  • the cofactor is typically ATP.
  • the amount of antibody bound cofactor can be assayed by using either the bacterial or firefly luciferase reactions. It is important that unbound compound-cofactor be removed so that only compound-cofactor bound to antibody is measured.
  • Reporter groups suitable for use in any of the methods include radioisotopes, fluorosphores, enzymes, luminescers, and dye particles.
  • receptor-based assays may be used. As disclosed within the present invention, certain compounds affect the enzyme activity of the Ca 2+ -ATPase (calcium pump) and the Na + ,K + -ATPase (sodium pump).
  • the compounds show specific inhibition of the Ca + -ATPase (with and without calmodulin activation) and Na + ,K + -ATPase, in intact cells, isolated plasma membranes and purified preparations of either enzyme.
  • a biological fluid sample may be tested for the presence or amount of a compound described above by detecting the presence or amount of specific inhibition (i.e., an IC50 of about 10 " ' M or more potent) or specific binding (i.e., about 10' liters/mol or higher) to the Ca 2 + -ATPase, or Ca 2 + -ATPase and Na + ,K + -ATPase.
  • Inhibition of the Ca 2+ -ATPase or Na + ,K + -ATPase by a sample containing a compound described above may be measured in a variety of assay formats.
  • the sample may be contacted with an active enzyme present in intact cells, isolated membranes, or purified form.
  • Purified enzymes may be derived from tissue or genetically engineered. Activities of either enzyme may be measured in a number of ways, e.g., by the amount of inorganic phosphate liberated from ATP.
  • the basal activity of the Ca 2+ -ATPase can be used or, for increased sensitivity, the enzyme can be activated by the addition of calmodulin at an appropriate concentration, such as about 30 nM.
  • Binding of a compound to the Ca + -ATPase or Na + ,K + -ATPase may also be measured in a variety of assay formats.
  • suitable preparations of either enzyme include intact cells, isolated membranes and purified forms of the enzymes.
  • reference herein to either enzyme also includes a portion of each enzyme which is capable of binding a compound described above. Such portions (i.e., peptides or polypeptides) may be isolated from native enzyme or constructed by a variety of known techniques.
  • a representative method for detecting the presence or amount of a compound in a sample is to measure the binding of a known quantity of the compound (which has been labeled with a reporter group) to either enzyme in the presence of a sample containing the compound. As the concentration of the compound in the sample increases, the amount of binding of the compound containing reporter group decreases which is reflected by a decrease in the amount of reporter group associated with the enzyme preparation.
  • Suitable reporter groups include those described above, such as chemiluminescent labels.
  • the compounds of the present invention may also be used for numerous therapeutic purposes.
  • Representative therapeutic uses include as a pressor agent, a potassium sparing diuretic, and an agent that alters cellular calcium levels (e.g., as a cardiotonic agent).
  • a compound is generally combined with a pharmaceutically acceptable carrier or diluent
  • Pharmaceutically acceptable carriers and diluents include water, physiological saline, alcohols, dimethyl sulfoxide (DMSO) and mixtures thereof.
  • the composition may be administered by a variety of routes, including oral, parenteral and transdermal administration.
  • the composition may be in pill, capsule or liquid form.
  • physiological saline is a preferred diluent.
  • DMSO is a preferred carrier.
  • the compounds described above have pharmacological effects which lead to vasoconstriction and thus are useful as pressor agents, i.e., as a substance for increasing blood pressure.
  • vasoconstriction and the resulting higher blood pressure are typically undesirable, there are situations, such as shock, where vasoconstriction and higher blood pressure are desirable.
  • a compound may be administered to treat shock and associated low blood pressure by causing vasoconstriction and elevation of blood pressure. Dangerously low blood pressure is an emergency condition frequently encountered in hospital and other settings.
  • the present invention also discloses that the compounds described above can function as a potassium sparing diuretic. Loss of potassium is a significant problem for patients taking conventional diuretics. Administration of a compound of the present invention increases the urinary excretion of water (diuresis) and sodium (natriuresis), without causing an increased loss of potassium.
  • additional therapeutic uses of the compounds described above include the treatment of imbalances in calcium and hydrogen.
  • Calcium imbalances have been associated with heart disorders, mood disorders and various bone diseases, such as osteoporosis.
  • Ca 2+ -ATPase activity may be inhibited and thus by altering cellular calcium levels is capable of treating a wide variety of disorders are capable of being treated.
  • warm-blooded animals possessing an excessive endogenous level of the compound may be treated by the administration of an antagonist to a compound described above.
  • Suitable antagonists are those which block the effects of an endogenous compound and include agents which block the ATPase receptors for the compound as well as agents which bind to the compound itself.
  • the ATPase receptors for the compound may be blocked using agents (e.g., derivatives of the compound) that bind to the receptors, but are incapable of significantly stimulating or inhibiting the activity of the receptor.
  • the compound may be directly blocked by an agent which binds to the compound.
  • agents include antibodies to the compound.
  • Example 1 provides the purification and chemical characterization of a compound of the present invention
  • Example 2 provides the chemical synthesis and radiolabeling of a compound
  • Example 3 discloses the inhibition of Ca 2+ -ATPase and Na + , K + - ATPase
  • Example 4 describes vasoconstrictive and natriuretic properties
  • Example 5 provides assays for antagonists.
  • the following examples are offered by way of illustration and not by way of limitation.
  • Fresh tissue e.g., kidney, removed in surgery or at autopsy, or cultured tissues, may be processed immediately or stored at -70°C.
  • Tissue is thawed, minced, and mixed with 2 equal volumes of physiological saline and 0.001% BHT. It is then homogenized in the cold with short bursts of rotary curring blades. Sediment is removed by centrifugation. The supernate is subjected to the purification steps described below. Tissue culture media are treated like plasma samples. 2. From blood or urine:
  • Fresh whole blood or urine is filtered through an ultrafilter to separate the low molecular weight compounds.
  • the plasma or serum can be separated from the blood prior to ultrafiltration.
  • the ultrafiltration step can be omitted.
  • Ultrafilters with cutoffs from 50,000 to 2,000 molecular weight (2,000 cutoff is preferred) can be used, e.g., YM-2 diaflo membranes (Amicon Corp.).
  • Supelco syringe filter tips and filters for renal patient hemodialysis (cuprophane) are also appropriate.
  • urease is added to the blood ultrafiltrate or to urine to eliminate urea.
  • the specific activity of the enzyme and the urea content of the filtrate are taken into account so that this step, which takes place at about 25°C, is of short duration. This step can be omitted, but separation is then less reproducible.
  • Urease treatment may be omitted in the clinical serum screening assay.
  • the volume is reduced by lyophylizing the sample, e.g., an ultrafiltrate of blood.
  • the dried residue is then reconstituted in H2O so that the final volume in mL is three times the weight of residue in grams, including the volume of 50% NH4OH used to titrate to pH 8.7.
  • Dry NaCl is added to saturate the solution, which facilitates extraction.
  • An antioxidant such as 0.01%-0.001% BHT should also be added.
  • the pH is adjusted to 8.6 with 1 to 3 M ammonium acetate. If tris or other buffers are used, ammonium salts or ammonium hydroxide should be added. The dilution should not exceed 3-fold for optimum recovery. Ammonium ions are needed for maximum extraction.
  • the pH can vary from 7.2 to 9.2, but maximum recovery is obtained at 8.6 to 8.8.
  • Solvent extraction of bulk preparations is accomplished in two steps. In the first, non-polar lipids are removed with benzene in a volume equaling the sample volume. The organic layer is discarded. The second extraction is to isolate the compound.
  • the purest preparations are accomplished with ethe ⁇ acetone (1:1), used in equal volume with the sample. This is a time- dependent step; recoveries increase with longer solvent exposure. One to twenty hours mixing before separation is satisfactory, with one hour adequate for the extraction for clinical screening serum tests. Ethe ⁇ acetone (5:7) may be used for bulk work. Other solvent systems will extract the compound and different proportions of contaminants.
  • the extraction is repeated two to three times, and the organic layers pooled. Centrifugation is needed to separate layers.
  • the solvents should be evaporated under N2 as rapidly as possible. Lyophylization is needed to dry the sample. From this step forward, exposure to light is restricted.
  • the residue of the organic phase is reconstituted in physiological saline or H2O to the original sample volume, or less if required by the sensitivity limits of the immunoassay or receptor assay in use. Resolubilization requires at least 30 minutes and adequate vortexing.
  • the organic residue is reconstituted in HPLC solvent, e.g., methanol:acetonitrile:water (15:15:70).
  • the sample is then subject to silicic acid column chromatography (e.g., with Biosil A, 100-200 mesh, Bio-Rad Laboratories, Inc., Richmond, Cal.).
  • a column (2 x 27 cm) is prepared in chlorofo ⁇ n:methanol:H2 ⁇ (60:35:2) at about 25°C.
  • the sample is applied in this solvent and eluted with it or a gradient to a chloroform:methanol:H2 ⁇ mixture of 60:35:3.
  • the compound elutes before most of the contaminating lipids and near the void volume of the column.
  • Fraction content is conveniently monitored by thin layer chromatography (TLC), enzyme inhibition or immunoassay.
  • TLC thin layer chromatography
  • this solvent is removed under N2 and/or vacuum, in the dark, and at temperatures less than 50°C.
  • the residue which may be oily in appearance, should not be dried excessively in the lyophylizer.
  • High pressure liquid chromatography is used to isolate the compound. HPLC grade solvents were used through the protocol. Water was deionized. When reducing solvent volume after HPLC purification, it is important to avoid lyophylizing the sample to diyness, as a loss may be encountered at this stage.
  • Affinity chromatography with anti-digoxin antibody or Na + ,K + -ATPase may be used to recover the compound after solvent (e.g., salt, alcohol, and acetonitrile) removal under nitrogen as an alternate to the lyophylization step.
  • solvent e.g., salt, alcohol, and acetonitrile
  • a C18 reverse phase column (7.8 mm x 30 cm semi-preparation, Waters, Milford, Mass.), coupled to a spectrophotometric detector set at 223 nm, is used. The column is thoroughly washed with ethanol then preconditioned with a preparation prepared from the pooled lipids which are eluted from the bulk extract under these chromatographic conditions and having retentions > 16 minutes.
  • Isolation of the compound on HPLC is a two-step process using a gradient elution system.
  • the solvent mix is 90% solvent A (H2O, MeOH, IsopropylOH; 70:15:15) and 10% solvent B (MeOH).
  • solvent A H2O, MeOH, IsopropylOH; 70:15:15
  • solvent B MeOH
  • This solvent mix is continued until the run termination time of thirty minutes.
  • the flow rate throughout the run is 2 ml/min. Fractions are collected every thirty seconds from fifteen to twenty minutes of the run time. The fractions are analyzed by radioimmunoassay for digoxin. The compound appears most frequently in fractions 17-18 minutes of run time.
  • a preferred isolation procedure for use in connection with immunoassays is as follows. At room temperature, 0.3 mL serum is added to each test tube (15 mL polypropylene conical centrifuge with screw caps). Ammonium acetate buffer (03 ml of 1.0 M at pH 8.6) and benzene (3.0 ml) are added into each test tube and vortexed for 30 seconds. The test tubes are then centrifuged for 10 minutes at room temperature, at about 1,500 x g.
  • the benzene is removed with a pipet, discarded, and the remaining organic layer and approximately 50% of the aqueous layer evaporated using a N2 stream in 44°C water bath.
  • Ethe ⁇ acetone (6 ml) is added to the test tubes, which are then vortexed gently.
  • the test tubes are placed on a rocker for 1.5 hours in the dark.
  • the ethe ⁇ acetone solvent is removed with pipette and saved in the dark at 4°C.
  • Each test tube is rinsed with 05 mL ethe ⁇ acetone mixture, vortexed, and the solvent removed with a pipette and added to the solvent stored in the dark.
  • the combined solvent is evaporated to dryness with N2 at 44°C.
  • the residue is reconstituted in 0.3 mL physiological saline or H2O.
  • the tube is vortexed well, allowing at least a 30 minute (preferably a 120 minute) solvation time.
  • the residue can be dissolved in minimal volumes of ethano methanol
  • the structure of the purified compound was determined by fast atom bombardment (FAB) mass spectral studies.
  • FAB mass spectra were recorded on VG-70 SEQ at 8 Kv acceleration voltage.
  • the FAB mass spectral data indicated the presence of a molecular ion at m/z (mass to charge ratio) of 716 (717 M+H, glycerol-HCl matrix).
  • Several peaks in the FAB mass spectra indicated the presence of a cardiac glycoside-like compound, with a digoxigenin-type nucleus (aglycone).
  • the characteristic peaks were obtained at m/z 393, 391, 375, 373, 357, 355, 339, and 337 (see, e.g., Greenwood et al., "Mass Spectrometiy in Drug Metabolism,” Frigerio and Ghisalberti, eds., pp. 174-189, Plenum Press, NY, 1976).
  • the peaks at m/z 393, 391, 375, 357, and 339 indicated the presence of digoxigenin-type nucleus with a saturated lactone ring.
  • the removal of a hydroxyl group from carbon-3 of the genin resulted in the peak observed at m/z 375. Further loss of a water molecule from this fragment resulted in a peak occurring at m/z 357.
  • the identity of the molecular ion occurring at m/z 716 was further established by running the FAB mass spectra of the sodium and potassium derivatives of the purified compound.
  • the sodium adduct of the compound indicated the presence of a distinct peak at m/z 739 (M+Na). While the potassium adduct resulted in an intense peak at m/z 755 (M+K).
  • FAB mass spectra of standard digoxigenin, dihydrodigoxigemn, digoxin, and dihydrodigoxin were obtained and compared with the FAB mass spectra of the purified compound.
  • the molecular formula was deduced as: C35H5 O ⁇ 5-
  • reaction mixture was boiled with constant stirring for 45 minutes and Hg(CN)2 (50 mg) was added along with HgBr2 (25 mg) and Bromohepta-O- acetyl-4-O- ⁇ -D-Glucopyranosyl-D-glucose (45 mg).
  • the solution was boiled for 20 hours. After 20 hours of boiling, the reaction mixture was diluted with chloroform and washed several times with a saturated solution of NaCl.
  • the chloroform-soluble fraction was dried with sodium sulfate (anhydrous), filtered and purified by preparative thin-layer chromatography (TLC) using chloroform : methanol (9.4 : 0.6) as the solvent system. This resulted in compound Q (50 mg).
  • Fetizon's reagent was prepared as follows. Celite (2 g) was added to a stirred solution of silver nitrate (2.26 g) in distilled water (13.5 ml). A solution of potassium bicarbonate (1.4 g) in distilled water (20 ml) was added slowly to the resulting homogenous suspension. After the addition, the stirring was continued for 15 minutes at room temperature. The yellow green precipitate thus formed was filtered and washed several times with diethyl ether. The resulting precipitates were dried in a light-shielded desiccator due to the reagent's sensitivity to light and air.
  • Radiolabeling Protocol Synthetic glycoside, after deacetylation, was dissolved in methanol and reduced with tritium gas using 5% Pd/C. The reaction was run for three hours and left overnight under hydrogen to reduce any unreacted compound remaining. The reaction mixture was then filtered through celite and purified by open column chromatography using silica gel (60-200 mesh) and 2.5% methanol in chloroform. Thin layer chromatography was performed using 10% methanol in chloroform. Sulfuric acid (5%) in ethanol was used as a spray reagent. Radioactivity was measured using Packard liquid scintillation analyzer model 2500TR.
  • a compound of the present invention was isolated as described in Example 1.
  • the compound was quantified by the Rianen 125 I-digoxin radioimmunoassay kit (New England Nuclear) with the modification of an addition of 1.8 mg/ml of bovine globulin fraction to facilitate precipitation.
  • the assay was linear from 0.1 ng/ml to 8 ng/ml digoxin equivalents while the imprecision was 0.28 ⁇ 0.04 ng digoxin equivalents/ml (X ⁇ SD).
  • the ATPases assayed were the Ca 2+ -ATPase and Na + ,K + - ATPase.
  • the ATPase assays were carried out in a total volume of 0.1 ml in flat bottom 96 well plates. Purified compound in 85% aqueous methanol was evaporated in the test wells under a stream of ultra-pure N2 at room temperature. ATP (3 mM) was added at the start of the reaction. The reaction was carried out for one hour at 37 °C. The reaction was te ⁇ ninated by the addition of sodium dodecyl sulfate (SDS) (0.83%).
  • SDS sodium dodecyl sulfate
  • Inorganic phosphate was determined colorimetrically in the plates. Ca 2+ -ATPase was measured in the basal and calmodulin activated states. Basal calcium ATPase activity was defined in the presence of ouabain and with added calcium (0.2 mM added and 0.1 mM in excess of EGTA). Calmodulin-activated Ca ⁇ ⁇ + "1" -ATPase activity was defined by the addition of calmodulin (30 nM).
  • Purified Ca 2+ -ATPase preparations are prepared by standard methodology. For example, plasma membranes from human red blood cells are isolated and solubilized with Triton X-100. The enzyme is separated from insoluble proteins by centrifugation. The resulting supernate is made 0.1% with azolecithin to stabilize the enzyme. The solution is passed over a calmodulin column in the presence of calcium to bind the enzyme. To remove extraneous proteins, the column is washed while the enzyme is still bound. The enzyme is released from the column by the addition of EDTA. The results of the assays are presented in Figures 3-6.
  • Female sheep weighing approximately 50 Kg are used for the experiments.
  • An arteriovenous cannula is surgically implanted in the carotid artery and jugular vein in the neck. At least 1 week is allowed to pass before beginning the experiments.
  • a standing sheep is placed in a gentle neck restraint in a cage.
  • the arteriovenous cannula is clamped and separated in the middle.
  • a Swan-Ganz cardiac catheter is passed into the pulmonary artery through the venous cannula. After verifying proper positioning, the catheter is left in situ to measure cardiac output by a thermal dilution method.
  • the mean arterial pressure is measured through the carotid artery cannula.
  • An infusion line is connected to the venous cannula and 72.5 mmol/L of NaCl is delivered at a constant rate with an infusion pump to replace normal losses.
  • An indwelling catheter is passed into the urinary bladder. The bladder is emptied completely and base line collections initialized.
  • Urine, blood and hemodynamic data are collected every 15 minutes for at least 1 hour to establish control conditions. After 1 hour of base line study, a compound is injected into the jugular vein. Urine, blood and hemodynamic data are collected at 5 minutes following the dose of the compound, and then at every 15 minutes thereafter for a period of 2 hours. The systemic vascular resistance is calculated from the cardiac output and the mean arterial pressure values. Glomerular filtration rate (GFR) is calculated as creatinine clearance and para-aminohippurate (PAH) clearance is used to measure effective renal plasma flow. Each sheep has at least a one week resting period between experiments. Typically, a total of six studies are conducted on two different sheep.
  • the dose of the compound generally ranges from 90 to 200 ng of digoxin equivalent (DE).
  • DE digoxin equivalent
  • the plasma and urine electrolytes, urea nitrogen, creatinine and glucose determinations are made on an Astra automated critical laboratory analyzer (Beckman Instruments, Fullerton, Calif.). PAH is measured with a spectrophotometric Bratton-Marshall method.
  • An antagonist (antibody or otherwise) to a compound of the present invention may be verified by in vitro and/or in vivo assays.
  • a competitive assay may be used in which radiolabeled compound is used to compete for binding sites on washed erythrocyte membranes. The presence of an antagonist in such an assay system results in a reduced proportion of radiolabeled compound binding to the membranes.
  • An alternative in vitro assay is to measure the amount of inhibition of Ca 2+ -ATPase by a compound in the presence and absence of an antagonist. The presence of an antagonist in such an assay system results in an increase in enzyme activity (i.e., reduction in inhibition of enzyme activity) relative to samples in which the antagonist is absent.
  • an in vivo assay may be used.
  • a sulfhydryl protective agent e.g., 1 mM dithiothreitol
  • the pH of the buffers is adjusted in the cold.
  • the protein content is determined according to the Gornall modification for the biuret method as adapted for the PARAMAX automated chemistry analyzer.
  • Washed membranes are used in a colorimetric in vitro assay where the reaction tubes are microtiter plates.
  • the colorimetric assay is based on phosphate quantitation after molybdic acid complex formation yielding a blue color.
  • the estimation of enzyme inhibition is based on the calculations as described in Li et al. (1990).
  • the contents per tube are those described by Li et al. (1990). Ultra pure water must be used in all reagent preparation.
  • the volumes used in the microtiter plate protocol are: 30 ⁇ l sample (H2O for 100% color controls), 10 ⁇ l compound, 2-8 ng/well, depending on the potency of the antagonist to compound and the preincubation time selected. (Omit from H2O controls) 20 ⁇ l buffer, 10 ⁇ l ouabain (if used), 10 ⁇ l water or calmodulin and 20 ⁇ l washed membranes. All of these cold reagents are added to the cooled plates and are protected from light.
  • the antagonist and the compound membrane mixture are preincubated with shaking at 37° as long as 90 minutes to allow complete competition for the membrane binding sites and also for complete temperature equilibration.
  • the reaction is initiated by adding 10 ⁇ l ATP.
  • the plates are then incubated for 60 minutes at 37° before 20 ⁇ l of 5% SDS is added to all wells with ATPase reactions.
  • Inorganic phosphate standards and H2O for the zero phosphate standard are added to the plate at this step, being placed in the empty wells carried around the perimeter.
  • the empty plate should be prescreened for spurious transmission from any scratched or dirty wells and these blank values used or ignored as is appropriate.
  • color reagent is added to all wells on the plate.
  • This reagent is made of 3 ml water, 6.5 ml molybdic acid, 7.9 ml 5% SDS, and 6.5 ml ascorbic acid which is 9% in water.
  • This is a color reagent known to one skilled in the art and has been described in Raess and Vincenzi (J. Pharmacol. Methods 4:391, 1980).
  • the color is allowed to develop for at least 20 minutes before measurement in a spectrometric plate reader.
  • the data calculated from the optical densities are ⁇ Moles phosphate formed/hour.
  • the added compound concentration selected should allow 70-90% inhibition when H2O is substituted for the antagonist.
  • the assay loses sensitivity at greater concentrations.
  • the reagent concentrations used in this competitive assay are adapted from the ATPase assay as described by Raess and Vincenzi (1980) to give the same reaction mixture concentrations, but diluted by 10%.
  • the membranes are used at 0.375 to .7 ⁇ g/ml concentration in the added reagent, which also contains saponin (.02%).
  • the calmodulin stock is 2.45 mg/ml which is prediluted to 0.059 mg/ml in a working stock and then diluted to 2 ⁇ m/ml in the working reagent. Dilutions are made in water.
  • the sheep model described in Example 4 may also be used to assess antagonists. Sheep are loaded with salt (in excess of 200-300 mmol of Na + ) in order to stimulate the production of glycoside. In this state, the basal renal excretion of various substances such as sodium and potassium and urine flow rates are obtained. The hemodynamic studies, including vascular resistance and systemic arterial pressure, are also measured. After obtaining these baseline values, an antagonist is administered and the above-mentioned studies are repeated. An effective antagonist leads to a drop in sodium excretion and urine flow rates, increase in potassium excretion, and a reduction in blood pressure and vascular resistance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention se rapporte à des composés utiles au dépistage et à la surveillance de l'hypertension chez des individus, à la correction d'une interférence dans l'évaluation de niveaux de digoxine chez des patients, et comme agents vasoconstricteurs, comme diurétiques entraînant une perte réduite de potassium, comme natriurétiques ou comme agents servant à modifier les niveaux de calcium cellulaire. Des procédés pour détecter la présence ou le niveau de ces composés sont aussi décrits.
EP91908957A 1990-05-07 1991-05-03 Nouveaux glycosides steroides utiles pour la detection precoce de l'hypertension Withdrawn EP0530224A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US520175 1983-08-04
US52017590A 1990-05-07 1990-05-07

Publications (1)

Publication Number Publication Date
EP0530224A1 true EP0530224A1 (fr) 1993-03-10

Family

ID=24071474

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91908957A Withdrawn EP0530224A1 (fr) 1990-05-07 1991-05-03 Nouveaux glycosides steroides utiles pour la detection precoce de l'hypertension

Country Status (6)

Country Link
EP (1) EP0530224A1 (fr)
AU (1) AU7794391A (fr)
IE (1) IE911531A1 (fr)
IL (1) IL98065A (fr)
WO (1) WO1991017176A2 (fr)
ZA (1) ZA913446B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922703A (en) * 1993-09-24 1999-07-13 The Procter & Gamble Company Urethane-containing aminosteroid compounds
EP0721459B1 (fr) * 1993-09-24 2000-05-31 The Procter & Gamble Company Nouveaux composes 14-aminosteroides contenant un oligosaccharide, et nouveaux procedes de traitement chimique a l'aide des nouveaux aminosteroides diastereoselectifs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546779A1 (de) * 1975-10-18 1977-04-28 Boehringer Mannheim Gmbh Neue 20.22-dihydro-cardenolid- glykoside
DE2707264A1 (de) * 1977-02-19 1978-08-24 Beiersdorf Ag Cardenolid-glucuronsaeuren, deren physiologisch vertraegliche salze und verfahren zu ihrer herstellung
DE2833472A1 (de) * 1978-07-29 1980-03-06 Beiersdorf Ag Digitoxigenin-monodigitoxosid-derivate und verfahren zu ihrer herstellung
DE2948835A1 (de) * 1979-12-05 1981-06-11 Basf Ag, 6700 Ludwigshafen Neue c-3-verzweigte cardenolid-glykoside, ihre herstellung und verwendung
DE3146899A1 (de) * 1981-11-26 1983-06-01 Boehringer Mannheim Gmbh, 6800 Mannheim Neue ketale von 3'''-dehydro-cardenolid-tridigitoxosiden, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9117176A2 *

Also Published As

Publication number Publication date
AU7794391A (en) 1991-11-27
IL98065A (en) 1997-01-10
IE911531A1 (en) 1991-11-20
WO1991017176A2 (fr) 1991-11-14
WO1991017176A3 (fr) 1991-12-12
IL98065A0 (en) 1992-06-21
ZA913446B (en) 1992-04-29

Similar Documents

Publication Publication Date Title
US5844091A (en) Antibody having binding specificity for human ouabain
Ludens et al. Purification of an endogenous digitalislike factor from human plasma for structural analysis.
US5770376A (en) Method of diagnosing and treating myocardial infarction and hypertension
CA2008360A1 (fr) Essai immunologique pour le diagnostic de l'infarctus du myocarde
Li et al. Bovine adrenals and hypothalamus are a major source of proscillaridin A-and ouabain-immunoreactivities
US4188189A (en) Quantitative testing for vitamin B12
US4780314A (en) Isolation and purification of a digitalis-like factor
EP0313244B1 (fr) Procédé pour augmenter la sensibilité de tests pour la mucine
EP1163270A1 (fr) Facteur de type dihydro-ouabainique, methodes de diagnostics, methodes et compositions therapeutiques
US4837170A (en) Monoclonal antibody, measuring method of glucosylated protein by utilizing the monoclonal antibody, and kit therefor
EP0530224A1 (fr) Nouveaux glycosides steroides utiles pour la detection precoce de l'hypertension
Heffetz et al. Antibodies directed against phosphothreonine residues as potent tools for studying protein phosphorylation
WO1991000519A1 (fr) Analyse de vitamine b¿12?
US5695756A (en) Methods for treating hypertension
Kobayashi et al. A Selective Immunoaffinity Chromatography for Determination of Plasma 1α, 25-Dihydroxyvitamin D3: Application of Specific Antibodies Raised against a 1α, 25-Dihydroxyvitamin D3–Bovine Serum Albumin Conjugate Linked through the 11α-Position
US4339390A (en) Preferential immunoreactivity of syn-isomer of cortisol derivative
WO1989003836A1 (fr) Facteurs associes a l'hypertension essentielle
Doerr Radioimmunoassay of oestrone in plasma
JP3414856B2 (ja) ジフェニルエーテル化合物の免疫学的測定方法
US5667811A (en) Na-K-ATPase inhibiting natriuretic substances
US6130211A (en) Phosphocholinate cardenolides
KOJIMA et al. Determination of proscillaridin in plasma by radioimmunoassay
US6190921B1 (en) Ouabain immunoassay and kit and ouabain labeled with 125I or fluorescent label
Németh et al. Gastrin radioimmunoassay: Description and application of a novel method
Parker Radioimmunoassay of cyclic nucleotides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950725